Sara Bonstein
CIK 1604019 · Chief Financial Officer · last filed 2026-06-12
Sara Bonstein is a Chief Financial Officer who has filed 129 SEC Form 4 insider transactions across 6 companies since 2014. The most recent filing, for XLO, was dated Jun 12, 2026. Across all open-market trades the lifetime net is −$44.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $9.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$9.31M
6
129
-$44.39M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| XLO | Director | — | $9.20 | — | $0 | 5 | 2026-06-12 |
| INSM | Chief Financial Officer | 69,082 | $134.75 | $9.31M | -$44.19M | 33 | 2026-06-05 |
| scPharmaceuticals Inc. (SCPH) Delisted | Director | — | $5.67 | — | $0 | 7 | 2025-10-07 |
| ONCOSEC MEDICAL Inc (ONCS) Delisted | CFO/COO | 1,881 | $0.28 | $521 | -$5.0K | 8 | 2020-01-21 |
| Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Chief Financial Officer | 226,670 | — | — | -$110.7K | 21 | 2018-04-03 |
| Ayala Pharmaceuticals, Inc. (ADXS.W) Delisted | Chief Financial Officer | 81,577 | — | — | -$83.9K | 32 | 2016-10-04 |
Recent Filings
129 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-12 | XLO | Grant (A) | — | $0 | EDGAR |
| 2026-06-05 | INSM | Sell (S) | −2,404 | -$245.9K | EDGAR |
| 2026-06-03 | INSM | Notice (144) | −2,404 | -$245.9K | EDGAR |
| 2026-05-15 | INSM | Sell (S) | −8,272 | -$961.0K | EDGAR |
| 2026-05-13 | INSM | Notice (144) | −8,272 | -$961.0K | EDGAR |
| 2026-02-04 | INSM | Sell (S) | −748 | -$116.9K | EDGAR |
| 2026-02-03 | INSM | Notice (144) | −748 | -$116.9K | EDGAR |
| 2026-01-08 | INSM | Notice (144) | −1,447 | -$252.0K | EDGAR |
| 2026-01-08 | INSM | Sell (S) | −4,642 | -$808.7K | EDGAR |
| 2026-01-07 | INSM | Notice (144) | −1,678 | -$293.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.